China's pharmaceutical foreign trade year-round steady to a good pattern has been formed

Since the beginning of this year, the global economy has continued to maintain a moderate recovery, and the growth rate of international trade has accelerated. In the field of medicine, although the traditional foreign trade competitive advantage weakens, industry and price competition is fierce, but with the continuous appearance of national policy effects, the new momentum to support the development of foreign trade in medicine is accelerating accumulation, quality benefits are steadily improved, the structure of foreign trade continues to optimize, medicine foreign trade year-round stable to a good pattern has been formed.
the first three quarters of 2017, China's total foreign trade in pharmaceuticals amounted to US$84,953 million, up 10.71 percent year-on-year. Of this total, exports were US$43.678 billion, up 5.61% YoY; Imports were $41.275 billion, up 16.66 percent year-on-year. The surplus was $2.403 billion, down 59.8 percent from a year earlier. Subdivided into three categories of commodities, Chinese medicine exports of 2.6 billion U.S. dollars, a slight decrease of 0.27% YoY; Western drug exports amounted to US$25,395 million, up 8.44% YoY; Exports of medical devices amounted to US$15,684 million, up 2.29% year-on-year.Analysis of the first three quarters
Import growth is better than exports, balanced development of pharmaceutical foreign trade
Imports of pharmaceutical products are the objective needs to promote China's economic and social development, but also the means of balanced development of pharmaceutical foreign trade. From January to September, China's imports of pharmaceutical products amounted to US$41,275 million, nearly balanced with exports, with import growth higher than exports by 11.05 percentage points. Among them, the price increase of Chinese medicine and medical devices increased and fell, and the price of Western medicine increased by two liters.
At present, China's imported products to high-end medical equipment, pharmaceutical equipment and Western medicine-based, and domestic industries are more complementary, can improve the domestic related supply, conducive to industrial restructuring, optimization and upgrading and people's livelihood improvement.The mainstream export market remained stable, with the "Belt and Road" growing significantly in the first three quarters, China's pharmaceutical exports reached 225 countries and regions, with Asia, Europe and North America as the main export markets, accounting for 86.8% of the total export volume of US$17.925 billion, US$11.42 billion and US$8.568 billion, respectively. Europe and North America are the main sources of imports of pharmaceutical products in China, of which imports from North America increased by 17.73 percent year-on-year and imports from Europe increased by 18.05 percent year-on-year, reflecting the continued solidity of the advantages of European and American products.
In addition, China's imports and exports of medicine from countries along the Belt and Road increased by 19.95 percent and 5.75 percent year-on-year, respectively, of which imports from Iran increased by 144.32 percent and imports from Turkey increased by 94.72 percent.private three-capital main force each have their own strengths and obvious benefits private and three-capital enterprises are the two main forces of China's medical insurance products foreign trade. The management team of the two has risen steadily, and the performance growth is more obvious.
the export sector, the number of private enterprise exporters accounted for 79.62 percent of the total number of export enterprises, accounting for 67.72 percent of exports and 53.69 percent of exports, exports increased by 8.05 percent year-on-year.
the import sector, the advantages of the three-capital enterprises are obvious, the number of importers accounted for 37.36 percent of the total imports, achieving 68.77 percent of the import volume and 61.05 percent of the import volume, the import volume increased by 19.34 percent year-on-year.coastal provinces and cities rebounded, the northeast and central and western regions of the hot and coldthe eastern coastal areas have always been The main production area of China's pharmaceutical products. From January to September, the top five exporters were Jiangsu, Zhejiang, Guangdong, Shanghai and Shandong, with Jiangsu, the top export province, reporting a 14.95 per cent increase. The three northeastern provinces and the central and western provinces are in sharp contrast: Ningxia grew by 28.32 percent, Xinjiang by 18.18 percent, and Guizhou and Yunnan also narrowed to the current 4.8 percent and 2.89 percent from a decline of 54.68 percent and 26.83 percent in the first quarter of this year. The three northeastern provinces fell across the board, with exports from Heilongjiang, Jilin and Liaoning falling by 19.98 per cent, 12.58 per cent and 2.76 per cent respectively. The weak pattern of east and west will not change much in the short term.five major export problems
1, the competition of RAW drugs disorderly countries in recent years vigorously promote supply-side structural reforms and progress, but the problem of overcapacity of bulk API is difficult to solve in the short term. In the face of fierce market competition, the export price of bulk RAW drugs all the way down, enterprises in order to compete for the market to fight a price war, profit margins are constantly squeezed. At the same time, some of the domestic small number of raw materials because of the manufacturers are small, low output, there is a monopoly price increase or by circulation, agent manufacturers exclusive buy-out situation, resulting in other preparation manufacturers have to take high prices, and thus push up the price of preparation exports. Some preparation enterprises because of the out-of-stock, directly abandoned such as simitidine, Lidokain, oxytocin and other market segments.
2, environmental pressure
is a large number of RAW drug enterprises due to environmental protection issues are facing the dilemma of stopping production. Such as Zhejiang Taizhou now has a number of pharmaceutical intermediate enterprises have been shut down, Beijing requires API manufacturers in November before the heating season all stop production and relocation, Beijing, Tianjin and Fujian require the pharmaceutical industry in the heating season to implement the wrong peak production.
is the pharmaceutical industry pollution standards gradually raised. The revised version of the "Pharmaceutical Industry Atmospheric Pollutant Emission Standards" refers to the experience of Europe, the United States and Japan and other countries, the implementation of the emission permit system, some of which are more stringent indicators than developed countries.
third is that the long-term production suspension of enterprises led to a shortage of domestic supply of related products, some international orders can not be executed normally, directly facing the risk of economic compensation and market loss.
need to pay attention to the "one size fits all" approach in some places. For example, some leading pharmaceutical enterprises in Hebei invested heavily in environmental upgrading, although the relevant requirements have been met, but in the face of production restrictions and environmental protection enterprises are not up to standard "the same."3, enterprise innovation ability is not strong recently the Medical Insurance Chamber of Commerce surveyed some economic and technological development zones, pharmaceutical industrial parks and related enterprises. Although all places attach more importance to scientific and technological innovation, there are still problems such as insufficient investment and serious homogenization of enterprise products. Some enterprises' product research and development expenses are even less than 1% of total sales revenue, which is far from the research and development investment of advanced countries. Part of the open area, industrial park is located in the midwest, high-level research and development resources are relatively scarce, high-level research and development personnel are relatively scarce, the basis of scientific and technological innovation is relatively weak, lack of high-quality factors such as attracting high-end talent, venture capital gathering platform carrier, enterprise innovation awareness and research and development capabilities are not strong, independent intellectual property rights and well-known brands are few, innovative leading enterprises are rare. 4, drug registration and certification difficulties the new drug evaluation cycle is a longer industry to reflect the more prominent problems, the current registration of an imported drug still needs 5 to 8 years. In addition, the international registration of drugs need to invest a lot of human and financial resources, and the relevant national registration certification period is short, high cost and other issues are also the focus of business attention. Such as Gansu Meikang reflects australia (TGA) certification cycle is short, only two years of validity, and certification costs are high, each product up to 400,000 to 500,000 yuan / time; Lanzhou Foci feedback product registration due to identity, country, the cost of a single variety from a few thousand dollars to tens of thousands of dollars.
5, enterprises to explore the international market is limited by the relevantAccording to the relevant provisions, commissioned processing varieties in the production, need to be in the production of the Drug Administration for the record, but only in the importing country as a "drug" status registration and obtain a document number, can be produced in the domestic GMP factory. Take traditional Chinese medicine as an example, it has not yet achieved legislation in many countries, the FDA's management of traditional Chinese medicine has been in accordance with the standards of the drug, but the category is still classified as "dietary supplements", thus not in line with China's filing requirements, affecting the business of related companies in the United States. In addition, China's preparation export needs to provide a certificate of drug export sales (CPP certificate), and Africa needs mostly different drug specifications from our country, in accordance with foreign specifications in the domestic application for registration and approval difficulties, resulting in our enterprises can not undertake this part of the drug orders, had to hand over the international market to Europe and the United States and India companies.
Full-year forecast
Pharmaceutical foreign trade increased by 10% to 12% in the first three quarters of this year In the first three quarters of this year, The overall situation of China's pharmaceutical foreign trade is better, the U.S. market and India, Brazil and other emerging markets to resume growth, conducive to the full-year export growth. Exports of bulk API, which account for nearly half of all pharmaceutical exports, increased by 8.86 percent year-on-year, while export volume increased by 7.04 percent year-on-year, reflecting the continued strong demand for bulk API in China in the international market, and with the tightening of domestic environmental law enforcement, the bulk was pushed up by Export prices of API, such as cardiovascular medicines, rose by 117.6 per cent, vitamins by 18.38 per cent YoY, and overall API export prices have changed from a 1.56 per cent decline in the first half of the year to a current 1.7 per cent increase. However, some enterprises feedback, although there is demand in the market, but the domestic supply of environmental factors difficult, the number of exports may shrink.
the growth momentum of china's imports is better. However, domestic incentives to use large-scale domestic equipment and tenders to reduce drug prices, large-scale medical equipment and high-priced patented drug imports will have an impact.
And with the state council and relevant competent departments in the early stage of the development of stable foreign trade, promote growth measures gradually implemented, coupled with the recent "on deepening the review and approval system reform to encourage drug medical device innovation" "decision on the adjustment of the registration management of imported drugs" and other policies have been implemented, will be conducive to the healthy and stable development of foreign trade in medicine.
analysis, based on last year's low foreign trade base, it is expected that in 2017 the import and export of medicines will grow by 10% to 12%, exports by 5% to 7%, and imports by 16% to 18%. : How
to improve the foreign trade environment of
medicine?Strengthen the supervision system, strengthen the classification and control efforts
it is recommended that relevant departments in the macro-level to strengthen the guidance, improve regulatory measures, through the fight against the export of fake and inferior pharmaceutical products, curb the vicious competition at low prices and other measures to eliminate in a timely manner quality standards non-compliant enterprises.
the field of environmental protection should adopt the "keep pressure" approach. For enterprises that meet the standards, they may be allowed to produce normally during the heating season, or some production lines to operate normally; Enterprises that fail to meet the standards should take strict measures to force them to strengthen environmental investment or phase them out.
, the normal production of exclusive varieties involving people's livelihood should be permitted. The government should formulate uniform pollutant treatment measures and standards so that enterprises can follow the rules. Scientific research institutions should increase research efforts in the field of environmental protection technology to guide enterprises to solve related pollution control problems and reduce costs.Cultivate leading enterprises and industrial groups and attach importance to innovation factors the government should increase its support efforts to cultivate enterprises with good economic benefits, strong driving capacity and great potential for development as key leading enterprises. Encourage strong enterprises to cooperate, enhance economies of scale, and build industrial clusters with a number of leading enterprises as the core.
To guide and encourage innovative resources, in the rational use of the technological advantages of leading enterprises at the same time, to build a joint innovation platform between enterprises, relying on long-term and stable scientific and technological innovation cooperation mechanism, enhance the scientific and technological innovation capabilities of enterprises under the jurisdiction, effectively promote the transformation and upgrading of enterprises.
strengthen the construction of standards system and accelerate the mutual recognition of international standardsIn view of the fact that enterprises pass the high cost of quality certification in different countries, we should strengthen the communication and consultation of intergovernmental regulations and technical standards, increase diplomatic involvement, and promote the docking and mutual recognition of international drug standards. We will work with the international community to develop regulatory cooperation and use multi-bilateral mechanisms to remove technical barriers to trade. At the same time, actively participate in international standard-setting. Such as the Medical Insurance Chamber of Commerce has formulated and issued three batches of plant extracts international business standards, at home and abroad and industry to achieve a better response, but also by the relevant government departments and inspection and testing institutions fully affirmed.
improve the import promotion system and improve the level of trade facilitationRelevant departments should pay attention to the role of pharmaceutical imports in the national import strategy, support the cultivation of professional import exhibition, and through long-term operation, form a complete industrial chain, strong professional, influential brand import exhibition; We will further simplify and relax some import management measures, revise and improve policies that are not in line with current development, and improve the overall coordination capacity of import links of customs, commercial inspection, document processing and other institutions. (Medical Economics)